Clinical Advances in Liver, Pancreas, and Biliary TractReplicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin
Section snippets
Patient Population
The Duke Hepatology Clinical Research Database and Repository is an ongoing registry of HCV-infected subjects initiated in 1992, representing a large, well-phenotyped collection of North American chronic HCV patients.10 All subjects referred to the Duke Liver Clinic with a diagnosis of HCV infection are eligible to be included in this database. Patients are enrolled at the time of their initial clinic visit, and informed consent is obtained for the collection and storage of serum, liver tissue,
Association of rs12979860 Genotype With SVR to PEG-IFN/RBV by Race
A description of the cohort used in our analysis of response to PEG-IFN/RBV is shown in Table 1. Patients predominantly were Caucasian, infected with HCV genotype 1, and broadly representative of a tertiary care chronic HCV cohort. Among patients treated with PEG-IFN/RBV, those included in this analysis differed only slightly from those excluded, with more HCV genotype 2/3–infected subjects (20% vs 11%; P = .02). As expected, responders to standard-of-care PEG-IFN/RBV treatment were
Discussion
Treatment decisions in patients with chronic hepatitis C infection currently are based on clinical, demographic, and virologic characteristics of infected patients. Although these may be helpful from a population point of view, for any individual patient and provider, these baseline pretreatment characteristics are inaccurate in predicting treatment response in hepatitis C patients infected with genotype 1, the most common genotype found in the United States. We have confirmed in this study
Acknowledgments
The authors would like to thank all of the study participants who contributed their biospecimens and data to the Duke Hepatology Clinic Database and Biorepository, and the authors acknowledge Diane Uzarski, Crystal Cates, Chris Delionbach, and Melissa Austin for continued maintenance of this valuable resource.
References (22)
- et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Lancet
(2001) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay
Genet Anal
(1999)- et al.
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics
Gastroenterology
(2006) Global burden of disease (GBD) for hepatitis C
J Clin Pharmacol
(2004)- et al.
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
N Engl J Med
(1999) - et al.
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
Ann Intern Med
(2006) - et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
N Engl J Med
(2002) - et al.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
Ann Intern Med
(2004) - et al.
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Nature
(2009) - et al.
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
Nat Genet
(2009)
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
Nat Genet
Cited by (309)
Predictive power of Interleukin–28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis
2021, Clinics and Research in Hepatology and GastroenterologyViral hepatitis
2019, Genomic and Precision Medicine: Infectious and Inflammatory DiseaseHigh frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan
2017, Kaohsiung Journal of Medical SciencesPrevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C
2016, Journal of the Formosan Medical Association
Conflicts of interest These authors disclose the following: Drs Thompson and McHutchison are co-inventors with Schering Plough on a patent application on the original finding of rs12979860 association with pegylated interferon and ribavirin treatment response in HCV infection; Drs McHutchison and Muir have received research funding from and acted in an advisory capacity for Schering Plough. The remaining authors disclose no conflicts.
Funding This study was funded in part by a generous grant from the David H. Murdock Institute for Business and Culture via the M.U.R.D.O.C.K. Study and award 1 UL1 RR024128-01 from the National Center for Research Resources, a component of the National Institutes of Health and National Institutes of Health Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of National Center for Research Resources or the National Institutes of Health. Dr Thompson received funding support from the Duke Clinical Research Institute, a generous research gift from the Richard B. Boebel Family Fund, the National Health and Medical Research Council of Australia, and the Gastroenterology Society of Australia.